Managing FCV-Associated FCGS: Treatment Options and Clinical Decisions

Once feline chronic gingivostomatitis (FCGS) is established, management can become challenging, particularly when severe oral inflammation and pain persist despite initial treatment. In cats with FCV-associated disease, several approaches have been explored, ranging from dental treatment to immunomodulatory therapies. 

Start With Local Oral Management^[1] 

Treatment options for FCGS include antibiotics combined with rigorous dental cleaning, along with daily chlorhexidine use. Corticosteroids and other immunosuppressive or immunomodulatory approaches, including chlorambucil and cyclosporine, have also been used. 

Full dental extraction is another important treatment option. Complete teeth extractions have been associated with clinical improvement in affected cats and may be considered when medical management does not provide adequate control. 

The treatment decision therefore needs to account for the severity of oral disease and whether a definitive dental approach is feasible. 

Where Does Interferon-ω Fit? 

Feline interferon-ω has been investigated as an alternative approach, particularly in cats in which full-mouth extraction is not possible or glucocorticoids are contraindicated. 

In one report, a cat that had undergone incomplete full-mouth extraction responded to feline interferon-ω, with clinical improvement occurring within six weeks. However, responses have not been uniform across clinical measures^[2]. 

A randomized, double-blind trial involving 39 FCV-infected cats with FCGS compared oral feline interferon-ω with prednisolone. There was no significant difference between treatments for most evaluated parameters, although pain scores were lower in the interferon group after two and three months^[3]. 

Another study involving 17 cats reported improvements in clinical and salivation scores with interferon-ω, but no improvement in mouth-opening pain, halitosis or mandibular lymphadenopathy^[1]. 

These findings suggest that interferon-ω may have a role in selected cases, but its effects should not be assumed to be uniform across all manifestations of FCGS. 

Consider the Patient’s Comorbidities 

Treatment selection may also depend on concurrent disease. In two diabetic cats with FCGS, oral feline interferon-ω was associated with clinical improvement and reduced insulin requirements^[4]. 

This may be particularly relevant when glucocorticoids are undesirable. Feline interferon-ω might provide an alternative when full dental extraction is not an option or when glucocorticoids are contraindicated, including in cats with diabetes. 

What About Stem Cell Therapy?^[1] 

Intravenous fresh adipose-derived mesenchymal stem cells have also been investigated. Autologous cells appeared more efficient than allogenic cells in the reported work. Among seven cats completing treatment, five responded: three achieved complete remission, and two showed substantial improvement. 

This approach remains one of several treatment options investigated for difficult FCGS cases rather than an established replacement for dental management. 

Match Treatment to the Clinical Situation 

FCV-associated FCGS should not be approached with a single treatment strategy. Dental cleaning, chlorhexidine, medical therapy and extraction remain important options, while interferon-ω and mesenchymal stem-cell therapy have been investigated for selected cases. 

The practical decision is to balance the severity of oral disease, response to initial management and feasibility of definitive dental treatment. In cats where extraction cannot be performed or glucocorticoids are unsuitable, alternative immunomodulatory approaches may warrant consideration.

References:

1. Hofmann-Lehmann R, Hosie MJ, Hartmann K, Egberink H, Truyen U, Tasker S, Belák S, Boucraut-Baralon C, Frymus T, Lloret A, Marsilio F. Calicivirus infection in cats. Viruses. 2022 Apr 29;14(5):937. https://www.mdpi.com/1999-4915/14/5/937
2. Southerden P, Gorrel C. Treatment of a case of refractory feline chronic gingivostomatitis with feline recombinant interferon omega. Journal of Small Animal Practice. 2007 Feb;48(2):104-6. https://catvirus.com/downloads/Southerden%202006%20JSAP.pdf
3. Hennet PR, Camy GA, McGahie DM, Albouy MV. Comparative efficacy of a recombinant feline interferon omega in refractory cases of calicivirus-positive cats with caudal stomatitis: a randomised, multi-centre, controlled, double-blind study in 39 cats. Journal of feline medicine and surgery. 2011 Aug;13(8):577-87. https://journals.sagepub.com/doi/pdf/10.1016/j.jfms.2011.05.012
4. Leal RO, Gil S, Brito MT, McGahie D, Niza MM, Tavares L. The use of oral recombinant feline interferon omega in two cats with type II diabetes mellitus and concurrent feline chronic gingivostomatitis syndrome. Irish veterinary journal. 2013 Oct 23;66(1):19. https://link.springer.com/content/pdf/10.1186/2046-0481-66-19.pdf